slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 46,381-46,410
Pages 3,679
Rows per page 30
Component
46,381-46,410 of 110,355
243
The slide uses red boxes and text annotations to highlight specific data points (M6 for ESS, M12 for cataplexy) that contradict expected outcomes.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
244
The slide uses a comparative analysis of clinical trial data to challenge the validity of the HARMONY 3 results.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
245
The slide uses red text and boxes to emphasize the contradiction between the trial paper's claims and the EMA's findings.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
247
The slide serves as a qualitative research summary based on 16 expert interviews.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
248
This slide presents a series of critical findings regarding market performance, competitive positioning, safety concerns, and marketing practices for the drug Wakix.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
249
The slide presents qualitative interview summaries as evidence of poor market reception.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
250
The slide presents anecdotal evidence from four specific prescribers, highlighting skepticism, reimbursement hurdles, and varying levels of adoption.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
251
The slide presents qualitative interview summaries highlighting drug discontinuation, safety concerns, and competitive disadvantages.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
252
The slide presents qualitative interview data from four distinct medical professionals, highlighting skepticism, lack of efficacy, and safety concerns.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
253
The slide presents a qualitative anecdote from a physician interview regarding drug safety.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
254
The slide uses direct quotes from a KOL to undermine the market potential of Wakix.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
255
The slide uses a Q&A format to present qualitative feedback from a medical expert.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
256
The slide uses direct quotes from a physician to highlight low adoption and skepticism.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
257
Includes highlighted text emphasizing the shift in sentiment from bullish to skeptical.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
258
The slide uses a Q&A format to highlight negative sentiment from a key opinion leader (KOL).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
259
The slide highlights a negative expert opinion on drug efficacy, contrasting it with the prescriber's own behavior.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
260
The slide uses a Q&A format to validate the negative sentiment expressed in the summary header.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
261
The slide presents qualitative feedback from a medical professional, highlighting skepticism and administrative barriers.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
262
The slide uses a Q&A format to validate the negative thesis regarding Wakix market performance.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
263
The slide uses a Q&A format to highlight the tightening reimbursement environment for a specific drug.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
264
Includes direct quotes from the physician regarding his clinical experience and frustrations with insurance paperwork.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
265
The slide uses a Q&A format to expose the physician's aggressive prescribing behavior and lack of clinical rigor.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
266
The slide highlights the physician's self-proclaimed influence and his personal relationship with sales reps, potentially exposing aggressive marketing tactics.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
267
The slide uses highlighted text to emphasize aggressive prescribing behavior and high patient penetration rates.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
268
The slide uses highlighted text to emphasize the doctor's skepticism regarding the drug's 'game-changer' status and the saturation of his patient base.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
269
The slide uses highlighted text to emphasize the doctor's lack of due diligence and surprise at the drug's high cost.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
270
Includes verbatim Q&A excerpts highlighting patient volume and discontinuation rates.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
271
The slide uses highlighted text to emphasize negative feedback from a key opinion leader.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
272
The slide uses a Q&A format to expose negative feedback regarding drug interactions and side effects.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
273
The slide uses a Q&A transcript format to validate the summary points provided at the top.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit